Sorafenib in advanced hepatocellular carcinoma JM Llovet, S Ricci, V Mazzaferro, P Hilgard, E Gane, JF Blanc, ...
New England journal of medicine 359 (4), 378-390, 2008
14912 2008 Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer D Cunningham, Y Humblet, S Siena, D Khayat, H Bleiberg, A Santoro, ...
New England journal of medicine 351 (4), 337-345, 2004
6507 2004 Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl (CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line … MER O’Brien, N Wigler, M Inbar, R Rosso, E Grischke, A Santoro, ...
Annals of oncology 15 (3), 440-449, 2004
1892 2004 Ceritinib in ALK -Rearranged Non–Small-Cell Lung Cancer AT Shaw, DW Kim, R Mehra, DSW Tan, E Felip, LQM Chow, DR Camidge, ...
New England Journal of Medicine 370 (13), 1189-1197, 2014
1833 2014 Phase II study of sorafenib in patients with advanced hepatocellular carcinoma GK Abou-Alfa, L Schwartz, S Ricci, D Amadori, A Santoro, A Figer, ...
Journal of clinical oncology 24 (26), 4293-4300, 2006
1565 2006 Observation of AM Sirunyan, A Tumasyan, W Adam, F Ambrogi, E Asilar, T Bergauer, ...
Physical review letters 120 (23), 231801, 2018
1042 * 2018 Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial A Younes, A Santoro, M Shipp, PL Zinzani, JM Timmerman, S Ansell, ...
The lancet oncology 17 (9), 1283-1294, 2016
994 2016 Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial J Bruix, JL Raoul, M Sherman, V Mazzaferro, L Bolondi, A Craxi, PR Galle, ...
Journal of hepatology 57 (4), 821-829, 2012
930 2012 Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer Elderly Lung Cancer Vinorelbine Italian Study Group
Journal of the National Cancer Institute 91 (1), 66-72, 1999
771 1999 Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm … P Armand, A Engert, A Younes, M Fanale, A Santoro, PL Zinzani, ...
Journal of Clinical Oncology 36 (14), 1428, 2018
700 2018 Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial S Horwitz, OA O'Connor, B Pro, T Illidge, M Fanale, R Advani, NL Bartlett, ...
The Lancet 393 (10168), 229-240, 2019
686 2019 Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study A Santoro, L Rimassa, I Borbath, B Daniele, S Salvagni, JL Van Laethem, ...
The lancet oncology 14 (1), 55-63, 2013
656 2013 Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial AX Zhu, M Kudo, E Assenat, S Cattan, YK Kang, HY Lim, RTP Poon, ...
Jama 312 (1), 57-67, 2014
650 2014 Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens-a … M Van Glabbeke, AT Van Oosterom, JW Oosterhuis, H Mouridsen, ...
Journal of Clinical Oncology 17 (1), 150-157, 1999
637 1999 Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for … A Santoro, T Tursz, H Mouridsen, J Verweij, W Steward, R Somers, ...
Journal of Clinical Oncology 13 (7), 1537-1545, 1995
631 1995 Increased MET gene copy number negatively affects survival of surgically resected non–small-cell lung cancer patients F Cappuzzo, A Marchetti, M Skokan, E Rossi, S Gajapathy, L Felicioni, ...
Journal of clinical oncology 27 (10), 1667, 2009
625 2009 Sorafenib: a review of its use in advanced hepatocellular carcinoma GM Keating, A Santoro
Drugs 69, 223-240, 2009
596 2009 SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma AX Zhu, O Rosmorduc, TRJ Evans, PJ Ross, A Santoro, FJ Carrilho, ...
Journal of Clinical Oncology 33 (6), 559-566, 2015
593 2015 Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase … F Ciceri, C Bonini, MTL Stanghellini, A Bondanza, C Traversari, ...
The lancet oncology 10 (5), 489-500, 2009
547 2009 Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study MC Garassino, BC Cho, JH Kim, J Mazières, J Vansteenkiste, H Lena, ...
The Lancet Oncology 19 (4), 521-536, 2018
542 2018 